These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24364808)

  • 21. Strategies To Design Selective Histone Deacetylase Inhibitors.
    Melesina J; Simoben CV; Praetorius L; Bülbül EF; Robaa D; Sippl W
    ChemMedChem; 2021 May; 16(9):1336-1359. PubMed ID: 33428327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural basis for the design and synthesis of selective HDAC inhibitors.
    Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
    Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Medicinal Chemistry Projects Requiring Imaginative Structure-Based Drug Design Methods.
    Moitessier N; Pottel J; Therrien E; Englebienne P; Liu Z; Tomberg A; Corbeil CR
    Acc Chem Res; 2016 Sep; 49(9):1646-57. PubMed ID: 27529781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zinc binding in HDAC inhibitors: a DFT study.
    Wang D; Helquist P; Wiest O
    J Org Chem; 2007 Jul; 72(14):5446-9. PubMed ID: 17579460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docking ligands into flexible and solvated macromolecules. 1. Development and validation of FITTED 1.0.
    Corbeil CR; Englebienne P; Moitessier N
    J Chem Inf Model; 2007; 47(2):435-49. PubMed ID: 17305329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors.
    Vanommeslaeghe K; Loverix S; Geerlings P; Tourwé D
    Bioorg Med Chem; 2005 Nov; 13(21):6070-82. PubMed ID: 16006131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors.
    Zhang Y; Feng J; Liu C; Zhang L; Jiao J; Fang H; Su L; Zhang X; Zhang J; Li M; Wang B; Xu W
    Bioorg Med Chem; 2010 Mar; 18(5):1761-72. PubMed ID: 20171895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of novel ferulic acid derivatives as potent histone deacetylase inhibitors.
    Wang F; Lu W; Zhang T; Dong J; Gao H; Li P; Wang S; Zhang J
    Bioorg Med Chem; 2013 Nov; 21(22):6973-80. PubMed ID: 24095016
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
    Wang DF; Helquist P; Wiech NL; Wiest O
    J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.
    Vannini A; Volpari C; Filocamo G; Casavola EC; Brunetti M; Renzoni D; Chakravarty P; Paolini C; De Francesco R; Gallinari P; Steinkühler C; Di Marco S
    Proc Natl Acad Sci U S A; 2004 Oct; 101(42):15064-9. PubMed ID: 15477595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calorimetric studies of the interactions of metalloenzyme active site mimetics with zinc-binding inhibitors.
    Robinson SG; Burns PT; Miceli AM; Grice KA; Karver CE; Jin L
    Dalton Trans; 2016 Jul; 45(29):11817-29. PubMed ID: 27373714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FlexE: efficient molecular docking considering protein structure variations.
    Claussen H; Buning C; Rarey M; Lengauer T
    J Mol Biol; 2001 Apr; 308(2):377-95. PubMed ID: 11327774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A steered molecular dynamics mediated hit discovery for histone deacetylases.
    Kalyaanamoorthy S; Chen YP
    Phys Chem Chem Phys; 2014 Feb; 16(8):3777-91. PubMed ID: 24429775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of novel potential scaffold for class I HDACs inhibition: An in-silico protocol based on virtual screening, molecular dynamics, mathematical analysis and machine learning.
    Fan C; Huang Y
    Biochem Biophys Res Commun; 2017 Sep; 491(3):800-806. PubMed ID: 28705738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
    Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
    ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Designing Hydroxamates and Reversed Hydroxamates to Inhibit Zinc-containing Proteases but not Cytochrome P450s: Insights from Quantum Mechanics and Protein-ligand Crystal Structures.
    Barker C; Lukac I; Leach AG
    Mol Inform; 2015 Sep; 34(9):608-14. PubMed ID: 27490712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structural biology of human metal-dependent histone deacetylases.
    Schapira M
    Handb Exp Pharmacol; 2011; 206():225-40. PubMed ID: 21879452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docking-enabled pharmacophore model for histone deacetylase 8 inhibitors and its application in anti-cancer drug discovery.
    Thangapandian S; John S; Sakkiah S; Lee KW
    J Mol Graph Model; 2010 Nov; 29(3):382-95. PubMed ID: 20870437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.